Psychopharmacology

Why Are There So Many Unsubstantiated Treatments in Autism?

Source: 
Research in Autism Spectrum Disorders
Date Published: 
December 27, 2012
Abstract: 

An estimated 32-92% of parents use complementary/alternative treatments for their children with ASD despite the lack of scientific evidence for the efficacy of these methods. In this article, researchers issue a call for a standardized way to select and evaluate treatments. Barriers to successful treatment, including high costs, limited availability, parental compliance and poor recommendations from professionals are discussed.

New Supplement in Pediatrics: Improving Health Care for Children and Youth With Autism and Other Neurodevelopmental Disorders

Source: 
Pediatrics
Date Published: 
November 1, 2012
Abstract: 

Access full articles on interventions, sleep and GI problems, health care coverage and more.

Roche and Seaside Therapeutics Enter Alliance to Develop Pharmacological Treatments for Autism

Source: 
http://www.marketwatch.com/story/roche-seaside-to-research-autism-treatments-2012-06-19?reflink=MW_news_stmp
Date Published: 
June 19, 2012
Abstract: 

Roche and Seaside Therapeutics have entered an alliance to develop pharmacological treatments for autism spectrum disorders and Fragile X Syndrome.

Antioxidants For Autism

Source: 
Biological Psychiatry
Date Published: 
June 1, 2012
Abstract: 

A specific antioxidant supplement containing N-Acetylcysteine, or NAC may be an effective therapy for some features of autism, according to a pilot trial from the Stanford University School of Medicine and Lucile Packard Children's Hospital that involved 31 children with the disorder.

A specific antioxidant supplement containing N-Acetylcysteine, or NAC may be an effective therapy for some features of autism, according to a pilot trial from the Stanford University School of Medicine and Lucile Packard Children's Hospital that involved 31 children with the disorder.

New Clinical Study Evaluates First Drug to Show Improvement in Subtype of Autism

Source: 
EurekAlert
Date Published: 
April 26, 2012
Abstract: 

In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).

Evidence behind autism drugs may be biased: study

Source: 
Reuters
Date Published: 
April 24, 2012
Abstract: 

Doctors' belief that certain antidepressants can help to treat repetitive behaviors in kids with autism may be based on incomplete information, according to a new review of published and unpublished research.

Clinical trials of new treatments for Fragile X are accepting participants

Source: 
FRAXA Research Foundation
Date Published: 
March 22, 2012
Abstract: 

Experimental new drugs, AFQ056 (an mGluR5 antagonist from Novartis) and STX209 (arbaclofen from Seaside Therapeutics) are in large scale trials.

New research might help explain how a gene mutation found in some autistic individuals leads to difficulties in processing auditory cues and paying spatial attention to sound.

Source: 
Science Daily
Date Published: 
February 2, 2012
Abstract: 

New research from Cold Spring Harbor Laboratory (CSHL) might help explain how a gene mutation found in some autistic individuals leads to difficulties in processing auditory cues and paying spatial attention to sound.

Study Finds Melatonin Eases Sleep Woes In Children With Autism

Source: 
MedicalXpress
Date Published: 
January 10, 2012
Abstract: 

A new Vanderbilt study shows that the over-the-counter supplement melatonin is promising in helping children with autism spectrum disorders (ASD), and their families, sleep better.

Dr. Eric London's Letter to the Editor of the New York Times

Source: 
New York Times
Date Published: 
January 1, 2012
Abstract: 

As a psychiatrist and the parent of an adult son with autism, I found “In Treating Disabled, Potent Drugs and Few Rules” (front page, Dec. 23) to be unfair and detrimental to the families of the developmentally disabled. Although any medication can be inappropriately administered, the wholesale denigration of psychotropic medication for this population is misplaced.

To the Editor:

As a psychiatrist and the parent of an adult son with autism, I found “In Treating Disabled, Potent Drugs and Few Rules” (front page, Dec. 23) to be unfair and detrimental to the families of the developmentally disabled. Although any medication can be inappropriately administered, the wholesale denigration of psychotropic medication for this population is misplaced.

People with autism do indeed have a brain disorder, and so using medications that treat the brain makes perfect sense. Many autistic patients have symptoms that warrant such medications for their own protection. These include behaviors like head banging, self-biting, sleeplessness and aggression.

I recently saw a patient in a developmental center who wore a helmet because of constant head-banging. When I asked what medications had been tried, staff members proudly told me that they had successfully avoided medicating this patient. But this decision came at a terrible cost to him, as his constant head-banging caused detachment of both retinas and blindness.

Articles implying that all psychotropic medications are inappropriate for this population do a terrible disservice. They make family members and staff members fearful of medications that can often make important quality-of-life improvements and, as a result, actually hurt the patients we desire to help.

ERIC LONDON
New York, Dec. 26, 2011